Publications

5891 Results

Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study

Authors
PA Philip;J Benedetti;C Fenoglio-Preiser;M Zalupski;H Lenz;E O'Reilly;R Wong;J Atkins;J Abbruzzese;C Blanke
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#LBA4509
Year
2007
Research Committee(s)
Gastrointestinal
Study Number(s)
S0205

S0216: a Southwest Oncology Group (SWOG) phase II trial of docetaxel (T), cisplatin (P), and fluorouracil (F) induction followed by accelerated fractionation/concomitant boost (AF/CB) radiotherapy (RT) and concurrent cisplatin for advanced head and neck squamous cell cancer (HNSCC)

Authors
DJ Adelstein;J Moon;E Hanna;SPG Giri;GM Mills;GT Wolf;SG Urba
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#6014
Year
2007
Research Committee(s)
Head and Neck
Study Number(s)
S0216

A phase II study of IV gemcitabine (G) and oral capecitabine (C) in patients (pts) with advanced renal cell cancer (RCC): results of Southwest Oncology Group study 0312

Authors
PJ Van Veldhuizen;M Hussey;PN Lara;PH Gumerlock;J Clark;MK Lange;D Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#15562
Year
2007
Research Committee(s)
Genitourinary
Study Number(s)
S0312

Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)--SWOG S0317

Authors
C Pan;M Hussey;P Lara;PC Mack;RB Nagle;J Dutcher;W Samlowski;J Clark;ED Crawford;MS Gordon
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#15516
Year
2007
Research Committee(s)
Genitourinary
Study Number(s)
S0317

Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)

Authors
PJ Hesketh;K Chansky;AJ Wozniak;P Mack;PN Lara;WA Franklin;FR Hirsch;J Crowley;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7536
Year
2007
Research Committee(s)
Lung
Study Number(s)
S0341

A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342

Authors
RS Herbst;K Chansky;K Kelly;JN Atkins;AM Davies;SR Dakhil;KS Albain;ES Kim;JJ Crowley;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7545
Year
2007
Research Committee(s)
Lung
Study Number(s)
S0342

Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): an analysis of SWOG 0412

Authors
BH Goldman;PN Lara Jr;TM Beer;PC Mack;HA Drabkin;WS Holland;ED Crawford;CW Ryan
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#5108
Year
2007
Research Committee(s)
Genitourinary
Study Number(s)
S0412

S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer

Authors
S Iqbal;B Goldman;HJ Lenz;CM Fenoglio-Preiser;CD Blanke
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#4621
Year
2007
Research Committee(s)
Gastrointestinal
Study Number(s)
S0413

A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). a Southwest Oncology Group (SWOG) trial.

Authors
SK Williamson;J Moon;CH Huang;P Guaglianone;GT Wolf;SG Urba
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#6044
Year
2007
Research Committee(s)
Head and Neck
Study Number(s)
S0420

SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas

Authors
AB El-Khoueiry;C Rankin;HJ Lenz;P Philip;SE Rivkin;CD Blanke
Journal / Conference
Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#4639
Year
2007
Research Committee(s)
Gastrointestinal
Study Number(s)
S0514